Skape Bio Unlocks Generalizable GPCR Drugs Using AI Protein Design
David Baker’s latest company is making medicines for a huge protein family once deemed undruggable. A new study generated miniproteins that target GPCRs across a diversity of receptor families implicated in itch and pain, cancer, metabolic disorders, and migraine. The post Skape Bio Unlocks Generalizable GPCR Drugs Using AI Protein Design appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.